California State Teachers Retirement System lessened its stake in Alkermes PLC (NASDAQ:ALKS) by 6.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,886 shares of the company’s stock after selling 20,043 shares during the period. California State Teachers Retirement System owned about 0.18% of Alkermes PLC worth $16,167,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ALKS. Russell Investments Group Ltd. increased its stake in shares of Alkermes PLC by 23.6% in the first quarter. Russell Investments Group Ltd. now owns 9,835 shares of the company’s stock worth $575,000 after buying an additional 1,877 shares during the last quarter. Neuberger Berman Group LLC increased its stake in shares of Alkermes PLC by 9.0% in the first quarter. Neuberger Berman Group LLC now owns 9,549 shares of the company’s stock worth $559,000 after buying an additional 787 shares during the last quarter. Teachers Advisors LLC increased its stake in Alkermes PLC by 11.8% during the first quarter. Teachers Advisors LLC now owns 155,311 shares of the company’s stock valued at $9,086,000 after purchasing an additional 16,354 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Alkermes PLC by 0.6% during the first quarter. PNC Financial Services Group Inc. now owns 7,104 shares of the company’s stock valued at $415,000 after purchasing an additional 42 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Alkermes PLC by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 194,531 shares of the company’s stock valued at $11,381,000 after purchasing an additional 2,891 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company’s stock.

Alkermes PLC (NASDAQ:ALKS) opened at 51.09 on Thursday. Alkermes PLC has a one year low of $42.75 and a one year high of $63.40. The firm’s market cap is $7.85 billion. The stock’s 50 day moving average is $51.16 and its 200 day moving average is $55.37.

Alkermes PLC (NASDAQ:ALKS) last announced its earnings results on Thursday, July 27th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.02. The company had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The business’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.01) earnings per share. On average, equities research analysts expect that Alkermes PLC will post ($0.04) earnings per share for the current year.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/10/19/alkermes-plc-alks-shares-sold-by-california-state-teachers-retirement-system.html.

ALKS has been the subject of several recent research reports. Jefferies Group LLC set a $69.00 target price on shares of Alkermes PLC and gave the company a “buy” rating in a research note on Friday, August 25th. J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. Barclays PLC lowered shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $66.00 to $50.00 in a research note on Monday. ValuEngine upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $62.56.

In other news, CAO Kathryn L. Biberstein sold 13,566 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the sale, the chief accounting officer now owns 70,455 shares in the company, valued at $3,613,636.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total value of $82,365.00. Following the sale, the director now owns 9,500 shares in the company, valued at approximately $521,645. The disclosure for this sale can be found here. Insiders have sold 18,066 shares of company stock worth $930,280 in the last 90 days. Company insiders own 5.34% of the company’s stock.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.